{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome+Coronavirus+2+%28SARS-CoV2%29&page=26",
    "query": {
      "condition": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2)",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 1233,
    "total_pages": 124,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome+Coronavirus+2+%28SARS-CoV2%29&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Acute+Respiratory+Syndrome+Coronavirus+2+%28SARS-CoV2%29&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T06:07:44.103Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04380961",
      "title": "A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Critical Confirmed Coronavirus Disease (COVID)-19"
      ],
      "interventions": [
        {
          "name": "Sirukumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Janssen Pharmaceutica N.V., Belgium",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 212,
      "start_date": "2020-04-24",
      "completion_date": "2021-06-24",
      "has_results": true,
      "last_update_posted_date": "2022-06-21",
      "last_synced_at": "2026-10-15T06:07:44.103Z",
      "location_count": 16,
      "location_summary": "Long Beach, California • Newport Beach, California • Fort Lauderdale, Florida + 13 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04380961"
    },
    {
      "nct_id": "NCT05960097",
      "title": "A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "CV0701 mRNA COVID-19 Vaccine (Low dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0701 mRNA COVID-19 Vaccine (Medium dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0701 mRNA COVID-19 Vaccine (High dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0601 mRNA COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0801 mRNA COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 692,
      "start_date": "2023-08-01",
      "completion_date": "2024-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-10-15T06:07:44.103Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Hollywood, Florida • Peoria, Illinois",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05960097"
    },
    {
      "nct_id": "NCT04950673",
      "title": "Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cognitive Decline",
        "Cognitive Dysfunction",
        "Brain Health",
        "Post CoV-2 Syndrome",
        "COVID Long-Haul"
      ],
      "interventions": [
        {
          "name": "Cognivue",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cognivue, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2021-07-21",
      "completion_date": "2024-04-30",
      "has_results": false,
      "last_update_posted_date": "2022-06-22",
      "last_synced_at": "2026-10-15T06:07:44.103Z",
      "location_count": 4,
      "location_summary": "Irvine, California • Visalia, California • Boca Raton, Florida + 1 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Visalia",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04950673"
    },
    {
      "nct_id": "NCT04910269",
      "title": "Outpatient Treatment With Anti-Coronavirus Immunoglobulin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID",
        "SARS-CoV2 Infection",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 741,
      "start_date": "2021-08-06",
      "completion_date": "2026-06-14",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-15T06:07:44.103Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Mather, California • Palo Alto, California + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Mather",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04910269"
    },
    {
      "nct_id": "NCT04860869",
      "title": "Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Covid19"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 23,
      "start_date": "2021-05-12",
      "completion_date": "2022-05-31",
      "has_results": true,
      "last_update_posted_date": "2024-10-28",
      "last_synced_at": "2026-10-15T06:07:44.103Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04860869"
    },
    {
      "nct_id": "NCT04748783",
      "title": "Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID19",
        "Coronavirus Infection",
        "SARS CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "Water",
          "type": "OTHER"
        },
        {
          "name": "Peroxyl",
          "type": "OTHER"
        },
        {
          "name": "Periogard",
          "type": "DRUG"
        },
        {
          "name": "Colgate Total Zero",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2021-03-26",
      "completion_date": "2021-04-07",
      "has_results": true,
      "last_update_posted_date": "2022-02-16",
      "last_synced_at": "2026-10-15T06:07:44.103Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04748783"
    },
    {
      "nct_id": "NCT04323761",
      "title": "Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "SARS-CoV2 Infection"
      ],
      "interventions": [
        {
          "name": "Remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-11-13",
      "last_synced_at": "2026-10-15T06:07:44.103Z",
      "location_count": 165,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 130 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04323761"
    },
    {
      "nct_id": "NCT04748185",
      "title": "Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Monoclonal B-Cell Lymphocytosis",
        "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "B-cell Non Hodgkin Lymphoma",
        "Hodgkin Lymphoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 358,
      "start_date": "2021-01-28",
      "completion_date": "2022-07-13",
      "has_results": false,
      "last_update_posted_date": "2023-07-10",
      "last_synced_at": "2026-10-15T06:07:44.103Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04748185"
    },
    {
      "nct_id": "NCT04347226",
      "title": "Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Sars-CoV2",
        "Hematological Malignancy"
      ],
      "interventions": [
        {
          "name": "BMS-986253",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2020-04-16",
      "completion_date": "2021-03-01",
      "has_results": true,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-10-15T06:07:44.103Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04347226"
    },
    {
      "nct_id": "NCT04473690",
      "title": "KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Low Dose of KBP-COVID-19",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High Dose of KBP-COVID-19",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "KBio Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 102,
      "start_date": "2020-12-30",
      "completion_date": "2022-10-14",
      "has_results": true,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-10-15T06:07:44.103Z",
      "location_count": 6,
      "location_summary": "West Palm Beach, Florida • Meridian, Idaho • Winston-Salem, North Carolina + 3 more",
      "locations": [
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Brownsville",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04473690"
    }
  ]
}